AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Nebuliser use in COPD is most common in severe disease with frequent exacerbations, high symptoms, and reduced lung function.

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today announced the enrollment of the first ...

People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...

In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...

Nebuliser use in COPD is highest in severe cases, reflecting worsening symptoms, frequent exacerbations, and the need for ...

Medically reviewed by Brian Bezack, DO Key Takeaways Over-the-counter (OTC) inhalers are not approved for treating COPD.

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...

As of early 2026, COPD remains the fifth-leading cause of death nationwide and carries a substantial economic burden, with ...